Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Zentiva Agrees To Buy Turkish Generics Firm
March 12, 2007
| A version of this story appeared in
Volume 85, Issue 11
Prague-based Zentiva has agreed to pay roughly $600 million for a 75% stake in Turkish generic drug supplier Eczacibasi. The deal includes a clause that allows Zentiva to buy the remaining 25% in two years. Zentiva says the acquisition furthers a strategy to expand its position in Central and Eastern Europe. IMS Health projects Turkey will be among the top 10 drug markets in the world by 2010. Eczacibasi, which had sales of about $260 million in 2006, markets branded generic drugs and offers contract manufacturing of active pharmaceutical ingredients.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter